CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02910531
NCT02910531Phase 2Completed
CompareCT.gov

The Effect of Lipoic Acid Natural Supplement on Cystine Stone Formation

Thomas Chi, MD·interventional·Posted Sep 22, 2016·Updated Apr 15, 2026

In Brief

A Phase 2 clinical trial evaluating Alpha lipoic acid and Placebo for Cystinuria. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This study evaluates how daily alpha lipoic acid supplementation affects cystine kidney stone recurrence. Half of the subjects will receive 1200 mg alpha lipoic acid orally daily for three years, while the other half will receive a placebo. The funding source for this clinical trial is FDA OOPD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystinuria
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 22, 2016
Enrollment StartJun 19, 2017
Primary CompletionDec 18, 2024
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 9.8 years ago

Interventions

Alpha lipoic aciddietary

Already mentioned in arm/group descriptions.

Placebodrug

Already mentioned in arm/group descriptions.